Clinical Trials Logo

Clinical Trial Summary

ACTH is a peptide secreted by pituitary gland and plays an important role in regulating cortisol secretion. ACTH is determined in plasma by immunoassays using specific antibodies. Its determination is difficult because of instability in whole blood. Several factors which influence ACTH stability in blood before analysis have been identified: temperature, hemolysis, time to centrifugation and presence of protease inhibitors. Published results on ACTH whole blood stability seem contradictory.

The objective of this study is to evaluate the effect of aprotinin in 10 healthy volunteers. ACTH measurements will be performed on cobas e602 (Roche Diagnostics, Mannheim, Germany).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04266587
Study type Interventional
Source University Hospital, Rouen
Contact Francois FRAISSINET
Phone +3323288
Email francois.fraissinet@chu-rouen.fr
Status Not yet recruiting
Phase N/A
Start date July 2020
Completion date November 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05279118 - Ketogenic Diet vs ACTH for the Treatment of Children With West Syndrome Phase 2/Phase 3
Completed NCT01294319 - Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men Phase 2
Recruiting NCT02019706 - Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome Phase 2